Vitalgen key facts
- Developer of gene therapy and biopharmaceutical innovation intended for global pharmaceutical companies, healthcare providers, and research institutions.
- Notable investors include GL Ventures, IDG Capital, Oriental Fortune Capital, China Merchants Venture Capital, Hebei Coastal Industry Investment Fund — 18 tracked in total.
- Status: Privately Held (backing).
Who backs Vitalgen
18+Membership and data by Private Market View
- ·The complete investor list: 18 names
- ·Watch Vitalgen: the Monday email on marks, rounds and moves
Vitalgen funding rounds
No funding rounds for Vitalgen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Vitalgen investors
18 investors are on record for Vitalgen, including GL Ventures, IDG Capital, Oriental Fortune Capital and China Merchants Venture Capital.
About Vitalgen
Developer of gene therapy and biopharmaceutical innovation intended for global pharmaceutical companies, healthcare providers, and research institutions. The company is committed to transforming cutting-edge gene delivery and gene editing technologies, thereby enabling clients to accelerate therapeutic development, expand treatment accessibility, and deliver life-changing interventions.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Website
- vitalgen.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Vitalgen doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.